Treatment of prostatic carcinoma with various types of estrogen derivatives.
D000368:Aged; D000728:Androgens / Q000097:blood; D004357:Drug Synergism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use*; D004967:Estrogens / Q000097:blood; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D011108:Polymers / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*
D000728:Androgens; D004967:Estrogens; D006065:Gonadotropins, Pituitary; D009588:Nitrogen Mustard Compounds; D009943:Organophosphorus Compounds; D011108:Polymers; D004961:Estramustine; D004997:Ethinyl Estradiol; D004958:Estradiol; D006854:Hydrocortisone